Skip to main content

Table 1 Subjects characteristics

From: Flow cytometric immunobead assay for quantitative detection of platelet autoantibodies in immune thrombocytopenia patients

Characteristics Test set 1 Test set 2 Pilot set
ITP (n = 201) Non-ITP (n = 126) HC (n = 207) ITP (n = 41) Non-ITP (n = 37) HC (n = 36) ITP (n = 8)
Disease subtype (n) Newly-diagnosed (63) Persistent (60) Chronic (78) NA NA NA NA NA Newly-diagnosed (8)
Gender (female/male, n) 45/18 38/22 48/30 56/70 76/131 24/17 11/26 13/23 5/3
Age (median, range, years) 53 (18, 86) 53 (9, 86) 54 (13, 83) 44 (13, 88) 48 (24, 91) 33 (5, 68) 42 (9, 64) 30 (21, 50) 38.5 (9, 69)
Platelet count (× 109/L)a 29.0 ± 16.9 41.0 ± 20.0 42.4 ± 20.3 41.5 ± 21.8 216.1 ± 56.8 38.2 ± 32.3 42.2 ± 31.0 211.4 ± 32.4 17.8 ± 9.9
Treatment (n, %)b NA 58 (96.7) 78 (100) NA NA 27 (65.9) NA NA NA
Steroids NA 51 (85.0) 75 (96.2) NA NA 27 (65.9) NA NA NA
Immunosuppressants NA 15 (25.0) 27 (34.6) NA NA 10 (24.4) NA NA NA
Splenectomy NA 0 (0) 3 (3.8) NA NA 0 (0) NA NA NA
Others NA 10 (16.7) 23 (29.5) NA NA 5 (12.2) NA NA NA
  1. Data are presented as mean ± SD, or percentage in parenthesis
  2. Steroids included dexathemethasone, prednisone or methylprednisolone; immunosuppressants included Cyclosporine A (CSA), Azathioprine (Aza) or Vindesine (VDS); others included Intravenous Immunoglobulin (IVIg), thrombopoietin (TPO) and Rituximab
  3. HC healthy controls, NA not applicable or not available
  4. Platelet count at first visit
  5. bAll the included patients did not receive any medical treatment for at least 1 month before sampling